



Life Without Limitations

A photograph of two young boys standing in a grassy field. The boy on the left is wearing an orange shirt and camouflage shorts. The boy on the right is wearing a yellow shirt, denim shorts, and a white neck brace. They are standing on a patch of ground that has a small puddle of water in front of them, which reflects their figures. To the right of the boys, there is a small blue and white flag on a stick. The background is a vast, open field under a clear sky.

OSSUR INVESTOR PRESENTATION

29 APRIL 2008



Life Without Limitations



OSSUR - Q1 2008

JON SIGURDSSON – PRESIDENT & CEO

HIGHLIGHTS Q1 2008



Life Without Limitations



- Sales USD 89.8 million
- Sales growth 12%, all organic
- EBITDA 25.6%
- EBITDA adjusted * 19.4%
- Healthy prosthetics sales growth across the border
- Excellent growth in traditional Europe
- Challenges at Gibaud and in bracing and support sales in Americas
- Divestment of the wound care product line

* Adjusted for \$5.5m one time income related to the sales of wound care operations



●● Americas

- Sales growth 4%
- Strong growth in prosthetics
- Bracing and support growth flat
- Makena distribution contract

●● EMEA¹⁾

- Sales growth 6%
- Strong growth in prosthetics
- Traditional Europe healthy growth in bracing and support
- Compression therapy sales decline 12%
- Favorable exchange rate developments

●● Asia



- Excellent 27% growth

1) EMEA growth presented in LCY. Favorable exchange rate developments result in significantly higher growth rates measured in USD.

SALES SPLIT BY SEGMENT AND GEOGRAPHY Q1 2008




Life Without Limitations



MAIN PRODUCT ACTIVITIES 2008



Life Without Limitations





FINANCIALS: Q1 2008

HJORLEIFUR PALSSON – CFO

FINANCIAL HIGHLIGHTS Q1 2008



Life Without Limitations



- Total sales USD 89.8 million
- Organic sales growth 12% in USD, 5% in local currency
- Profit from operations USD 17 million, up 320% from Q1 2007
- EBITDA 25.6% compared to 12.7% in Q1 2007
- EBITDA adjusted 19.4% compared to 14.3% in Q1 2007
- Net profit USD 6.7 million, compared to net loss of 2.7 million in Q1 2007
- Cash EPS diluted 2.98 US cents, up by 231% from Q1 2007
- EPS diluted 1.58 US cents, compared to -0.90 US cents in Q1 2007

INCOME STATEMENTS Q1 2008



Life Without Limitations

Income Statements (USD '000)	Q1 2008	% of sales	Q1 2007 ¹⁾	% of sales	Change
Net sales	89,754	100.0%	80,380	100.0%	11.7%
Cost of goods sold	(36,577)	-40.8%	(36,004)	-44.8%	1.6%
Gross profit	53,177	59.2%	44,376	55.2%	19.8%
Other income	5,739	6.4%	320	0.4%	1691.2%
Sales & marketing expenses	(23,499)	-26.2%	(22,233)	-27.7%	5.7%
Research & development expenses	(5,424)	-6.0%	(5,052)	-6.3%	7.4%
General & administrative expenses	(12,952)	-14.4%	(13,353)	-16.6%	-3.0%
Profit from operations	17,041	19.0%	4,058	5.0%	319.9%
Financial income /(expenses)	(9,043)	-10.1%	(7,852)	-9.8%	15.2%
Profit/(loss) before tax	7,998	8.9%	(3,794)	-4.7%	n/a
Income tax	(1,314)	-1.5%	1,088	1.4%	n/a
Net profit for the period	6,684	7.4%	(2,706)	-3.4%	n/a
EBITDA	22,950	25.6%	10,240	12.7%	124.1%
EBITDA adjusted²⁾	17,449	19.4%	11,528	14.3%	51.4%

1) Q1 2007 cost of goods sold and operating expenses at Gibaud have been reclassified in accordance with IFRS accounting principles

2) Excluding \$ 5.5m sales gain related to the divestment of the wound care product line in Q1 2008.

BALANCE SHEETS 31 MARCH 2008



Life Without Limitations

USD '000	31 March 2008	31 December 2007	% Change
Fixed assets	508,827	503,564	1%
Current assets	142,531	132,257	8%
Total assets	651,358	635,821	2%
Stockholders' equity	259,336	250,282	4%
Long-term liabilities	251,513	239,361	5%
Current liabilities	140,509	146,178	-4%
Total equity and liabilities	651,358	635,821	2%
Net Debt / EBITDA LTM	3.6	4.4	
Net Debt / EBITDA LTM adj.*	4.4	4.8	
Equity ratio	40%	39%	

* Excluding \$ 5.5m sales gain related to the divestment of the wound care product line.


CASH AND CAPEX



Life Without Limitations



Cash Ratios (USD '000)	Q1 2008	% of sales	Q1 2007	% of sales	Change
Working capital provided by operating activities	19,505	22%	5,504	7%	254%
Net cash provided by operating activities	14,278	16%	2,111	3%	576%
Cash EPS diluted (US cents)	2.98		0.90		230%



MAIN SHAREHOLDERS 31 MARCH 2008



Life Without Limitations

Name		Shares	Percentage
William Demant Invest A/S	Investment Fund	144,952,402	34.27
Eyrir Invest ehf	Investment Company	84,040,215	19.87
Mallard Holding S.A.	Founder & Family	37,526,769	8.87
Vik Investment Holding S.a.r.L.	President & CEO	24,446,907	5.78
ATP-Arbejdmarkedets Tillægspension	Pension Fund	14,660,194	3.47
Gildi -lífeyrissjóður	Pension Fund	13,274,891	3.14
Lífeyrissjóður verslunarmanna	Pension Fund	7,870,283	1.86
Sameinaði lífeyrissjóðurinn	Pension Fund	7,673,288	1.81
Arion safnreikningur	Custody bank	7,593,047	1.80
Lífeyrissjóðir Bankastræti 7	Pension Fund	6,806,863	1.61
BYR sparissjóður	Bank	5,434,392	1.28
Landsbanki Íslands hf,	Bank	4,460,637	1.05
Stafir lífeyrissjóður	Pension Fund	3,637,127	0.86
Mycenaean Holding S.a.r.L.	VP of R&D	3,560,347	0.84
Fidelity Funds	Investment Fund	2,544,484	0.60
Top 15 Shareholders		368,481,846	87.11
Others		54,518,154	12.89
Total number of shares		423,000,000	100.00

